Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Logos Global Management LP
Form 13F · Q2 2026

Logos Global Management LP

CIK 1792126Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$2.3B
Reported book value
68
Positions
12
Quarters on record
Top 50
Positions

Logos Global Management LP — holdings

Top 50 positions of 68, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ERAS Erasca Inc12.2M+9.0%$223M9.6%
2ABIVAX SA Abivax Sa1.0M+51.7%$136M5.9%
3RVMD Revolution Medicines Inc700,000−65.0%$131M5.6%
4IDYA Ideaya Biosciences Inc3.0M−13.0%$112M4.8%
5BNTX Biontech Se1.0M—$94M4.1%
6VERA Vera Therapeutics Inc2.2M—$94M4.1%
7TNGX Tango Therapeutics Inc2.9M−5.0%$89M3.8%
8PRAX Praxis Precision Medicines I260,000−8.8%$87M3.7%
9CLDX Celldex Therapeutics Inc New2.1M+366.7%$78M3.4%
10DNTH Dianthus Therapeutics Inc800,000+100.0%$78M3.4%
11CGON Cg Oncology Inc1.0M+73.9%$71M3.1%
12IRON Disc Medicine Inc875,000+56.2%$64M2.8%
13MAZE Maze Therapeutics Inc1.9M+56.7%$58M2.5%
14DYN Dyne Therapeutics Inc2.5M+82.1%$57M2.4%
15MLTX Moonlake Immunotherapeutics2.7M+78.3%$52M2.2%
16OCUL Ocular Therapeutix Inc5.3M+37.7%$52M2.2%
17DSGN Design Therapeutics Inc3.0M+53.8%$43M1.9%
18OLEMA PHARMACEUTICALS INC Olema Pharmaceuticals Inc3.2M+0.0%$40M1.7%
19BLTE Belite Bio Inc250,000—$38M1.7%
20QUIT Achieve Life Science Inc5.4M—$35M1.5%
21TRVI Trevi Therapeutics Inc1.9M−21.7%$35M1.5%
22COGT Cogent Biosciences Inc900,000—$35M1.5%
23AVBP Arrivent Biopharma Inc1.0M+185.7%$35M1.5%
24CBIO Crescent Biopharma Inc.1.9M+293.8%$34M1.5%
25CMPS Compass Pathways Plc2.2M—$32M1.4%
26MLYS Mineralys Therapeutics Inc1.1M—$28M1.2%
27REPL Replimune Group Inc2.5M—$28M1.2%
28XENE Xenon Pharmaceuticals Inc450,000+0.0%$27M1.2%
29GPCR Structure Therapeutics Inc500,000+0.0%$27M1.2%
30IMVT Immunovant Inc665,000−38.1%$26M1.1%
31JBIO Jade Biosciences Inc1.1M+181.2%$25M1.1%
32ELVN Enliven Therapeutics Inc465,000−13.9%$24M1.0%
33MANE Veradermics Inc180,000+620.0%$22M1.0%
34AVTX Avalo Therapeutics Inc1.1M+283.3%$21M0.9%
35RCUS Arcus Biosciences Inc650,000−45.8%$20M0.9%
36SMMT Summit Therapeutics Inc1.4M—$20M0.8%
37IMCR Immunocore Hldgs Plc600,000−60.0%$19M0.8%
38LBRX Lb Pharmaceuticals Inc585,000−36.1%$19M0.8%
39NERV Minerva Neurosciences Inc3.3M+2.3%$18M0.8%
40FTH Faeth Therapeutics Inc722,020+2306.7%$18M0.8%
41CRSP Crispr Therapeutics Ag300,000—$16M0.7%
42DBVT Dbv Technologies S A915,000—$15M0.6%
43PBLS Parabilis Medicines Inc525,000—$14M0.6%
44RYTM Rhythm Pharmaceuticals Inc125,000−72.2%$14M0.6%
45VOR Vor Biopharma Inc650,000−13.3%$12M0.5%
46SRRK Scholar Rock Hldg Corp200,000—$11M0.5%
47IMMX Immix Biopharma Inc1.0M−18.4%$10M0.4%
48QTTB Q32 Bio Inc800,000—$10M0.4%
49ODTX Odyssey Therapeutics Inc521,736—$10M0.4%
50ANNX Annexon Inc1.5M—$9M0.4%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.